Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD1) or programmed death ligand 1 (PD-L1) have already substantially improved the outcomes of patients with many types of cancer, but only 20%–40% of patients benefit from these therapies (5). Here, PDCD1 is linked to cancer.